Testing effectiveness (Phase 2)Looking for participantsNCT05907759
What this trial is testing
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Who this might be right for
Lymphoma, Primary Effusion
National Cancer Institute (NCI) 28